hBD-1 vs BYM338
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
| Property | hBD-1 | BYM338 |
|---|---|---|
| Category | Dental & Oral | Muscle & Performance |
| Full Name | Human beta-defensin 1 | Bimagrumab (BYM338) |
| Molecular Weight | 4490 Da | ~148 kDa |
| Half-Life | minutes to hours | ~2-3 weeks |
| Amino Acids | 36 | N/A |
| Typical Dose | 1-10 µg/mL in experimental studies | 10-30 mg/kg IV in trials |
| Route | Topical/Intraoral | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 140 |
| Research Status | Pre-clinical | Clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.